Literature DB >> 21994003

Contribution of GPR30 for 1,25 dihydroxyvitamin D₃ protection in EAE.

Sandhya Subramanian1, Lisa M Miller, Marjorie R Grafe, Arthur A Vandenbark, Halina Offner.   

Abstract

Previous studies have demonstrated that vitamin D3-mediated protection in EAE occurs only in females and is dependent on the presence of diestrus levels of 17β-estradiol (E2). To evaluate the role of estrogen receptors in vitamin D3 treatment of EAE, we compared disease severity, CNS histopathology and immunological responses in vehicle and calcitrol (1,25 dihydroxyvitamin D₃) treated WT C57BL/6 mice vs. GPR30 membrane estrogen receptor (MER) knockout mice with MOG-35-55 peptide-induced EAE. Our results demonstrated that vitamin D₃-mediated prevention of clinical signs, CNS cellular lesions and demyelination observed in WT mice was abrogated in GPR30-KO mice with EAE. Regulatory effects of vitamin D₃ treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. These results demonstrate for the first time that the MER is a key contributor to the E2-dependent effects of vitamin D₃-mediated protection in EAE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21994003     DOI: 10.1007/s11011-011-9266-6

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  22 in total

1.  A transmembrane intracellular estrogen receptor mediates rapid cell signaling.

Authors:  Chetana M Revankar; Daniel F Cimino; Larry A Sklar; Jeffrey B Arterburn; Eric R Prossnitz
Journal:  Science       Date:  2005-02-10       Impact factor: 47.728

2.  1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis.

Authors:  Christopher G Mayne; Justin A Spanier; Lance M Relland; Calvin B Williams; Colleen E Hayes
Journal:  Eur J Immunol       Date:  2011-02-01       Impact factor: 5.532

3.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.

Authors:  Kassandra L Munger; Lynn I Levin; Bruce W Hollis; Noel S Howard; Alberto Ascherio
Journal:  JAMA       Date:  2006-12-20       Impact factor: 56.272

4.  Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.

Authors:  Elias A Said; Franck P Dupuy; Lydie Trautmann; Yuwei Zhang; Yu Shi; Mohamed El-Far; Brenna J Hill; Alessandra Noto; Petronela Ancuta; Yoav Peretz; Simone G Fonseca; Julien Van Grevenynghe; Mohamed R Boulassel; Julie Bruneau; Naglaa H Shoukry; Jean-Pierre Routy; Daniel C Douek; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2010-03-07       Impact factor: 53.440

5.  Increased vitamin D serum levels correlate with clinical improvement of rheumatic diseases after Dead Sea climatotherapy.

Authors:  Marco Harari; Elisabeth Dramsdahl; Shraga Shany; Yael Baumfeld; Arieh Ingber; Victor Novack; Shaul Sukenik
Journal:  Isr Med Assoc J       Date:  2011-04       Impact factor: 0.892

6.  Multiple sclerosis: a geographical hypothesis.

Authors:  I P Carlyle
Journal:  Med Hypotheses       Date:  1997-12       Impact factor: 1.538

7.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.

Authors:  E J Filardo; J A Quinn; K I Bland; A R Frackelton
Journal:  Mol Endocrinol       Date:  2000-10

8.  Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene.

Authors:  I M Byrne; L Flanagan; M P Tenniswood; J Welsh
Journal:  Endocrinology       Date:  2000-08       Impact factor: 4.736

9.  Therapeutic effect of vitamin D3 in multiple sclerosis patients.

Authors:  Ghasem Mosayebi; Ali Ghazavi; Keyvan Ghasami; Yahya Jand; Parviz Kokhaei
Journal:  Immunol Invest       Date:  2011-05-04       Impact factor: 3.657

10.  Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression.

Authors:  Faye E Nashold; Karen M Spach; Justin A Spanier; Colleen E Hayes
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

View more
  7 in total

Review 1.  What have we learned about GPER function in physiology and disease from knockout mice?

Authors:  Eric R Prossnitz; Helen J Hathaway
Journal:  J Steroid Biochem Mol Biol       Date:  2015-07-16       Impact factor: 4.292

Review 2.  The Roles of Orphan G Protein-Coupled Receptors in Autoimmune Diseases.

Authors:  Mingming Zhao; Zheyu Wang; Ming Yang; Yan Ding; Ming Zhao; Haijing Wu; Yan Zhang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-07       Impact factor: 8.667

Review 3.  Nuclear hormone receptors in demyelinating diseases.

Authors:  Rocío I Zorrilla Veloz; Takese McKenzie; Bridgitte E Palacios; Jian Hu
Journal:  J Neuroendocrinol       Date:  2022-06-22       Impact factor: 3.870

4.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

Review 5.  Estrogen biology: new insights into GPER function and clinical opportunities.

Authors:  Eric R Prossnitz; Matthias Barton
Journal:  Mol Cell Endocrinol       Date:  2014-02-12       Impact factor: 4.102

6.  Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice.

Authors:  Anirban Banerjee; Jianming Wang; Sheetal Bodhankar; Arthur A Vandenbark; Stephanie J Murphy; Halina Offner
Journal:  Transl Stroke Res       Date:  2013-10       Impact factor: 6.829

Review 7.  G Protein-Coupled Estrogen Receptor in Immune Cells and Its Role in Immune-Related Diseases.

Authors:  George Notas; Marilena Kampa; Elias Castanas
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-02       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.